Medicina
Département
Eli Lilly and Company
Indianapolis, EE. UU.Publications en collaboration avec des chercheurs de Eli Lilly and Company (114)
2024
2023
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90
-
Evaluating the Impact of a Training Program in Shared Decision-Making for Neurologists Treating People with Migraine
Neurology and Therapy, Vol. 12, Núm. 4, pp. 1319-1334
-
Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence
Geburtshilfe und Frauenheilkunde, Vol. 84, Núm. 2, pp. 164-184
-
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Clinical Lung Cancer, Vol. 24, Núm. 5, pp. 415-428
-
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
ESMO Open, Vol. 8, Núm. 4
2022
-
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
npj Breast Cancer, Vol. 8, Núm. 1
-
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
RMD Open, Vol. 8, Núm. 1
-
Adaptation and Validation of the Spanish Version of Decisional Conflict Scale in People with Migraine in Spain
Patient Preference and Adherence, Vol. 16, pp. 3291-3302
-
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192
-
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
Future oncology (London, England), Vol. 18, Núm. 28, pp. 3133-3141
-
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
Nature communications, Vol. 13, Núm. 1, pp. 1878
-
Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients with High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy - Reply
JAMA Oncology
-
Treatment with Adjuvant Abemaciclib Plus Endocrine Therapy in Patients with High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
JAMA Oncology, Vol. 8, Núm. 8, pp. 1190-1194
-
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64
2021
-
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
npj Breast Cancer, Vol. 7, Núm. 1
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
-
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
The Lancet Respiratory Medicine, Vol. 9, Núm. 12, pp. 1407-1418
-
Factors Associated with Health-Related Quality of Life in Psoriatic Arthritis Patients: A Longitudinal Analysis
Rheumatology and Therapy, Vol. 8, Núm. 3, pp. 1341-1354
-
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Oncologist, Vol. 26, Núm. 1, pp. e53-e65